Back

Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers

Boruah, N.; Hoyos, D.; Moses, R.; Hausler, R.; Desai, H.; Le, A. N.; Good, M.; Kelly, G.; Raghavakaimal, A.; Tayeb, M.; Narasimhamurthy, M.; Doucette, A.; Gabriel, P.; Feldman, M. J.; Park, J.; Lopez de Rodas Gregorio, M.; Schalper, K. A.; Goldfarb, S. B.; Nayak, A.; Levine, A. J.; Greenbaum, B. D.; Maxwell, K. N.

2024-04-07 genetics
10.1101/2024.04.03.588009 bioRxiv
Show abstract

Pathogenic germline TP53 alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer is the most common cancer in LFS females. We performed first of its kind multimodal analysis of LFS breast cancer (LFS-BC) compared to sporadic premenopausal BC. Nearly all LFS-BC underwent biallelic loss of TP53 with no recurrent oncogenic variants except ERBB2 (HER2) amplification. Compared to sporadic BC, in situ and invasive LFS-BC exhibited a high burden of short amplified aneuploid segments (SAAS). Pro-apoptotic p53 target genes BAX and TP53I3 failed to be up-regulated in LFS-BC as was seen in sporadic BC compared to normal breast tissue. LFS-BC had lower CD8+ T-cell infiltration compared to sporadic BC yet higher levels of proliferating cytotoxic T-cells. Within LFS-BC, progression from in situ to invasive BC was marked by an increase in chromosomal instability with a decrease in proliferating cytotoxic T-cells. Our study uncovers critical events in mutant p53-driven tumorigenesis in breast tissue.

Published in Nature Communications (predicted rank #3) · training set

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.